This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the U.S. I am a U.S. resident I am a patient outside the U.S.
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

TASIGNA is now indicated for patients newly diagnosed with Ph+

Is it possible to improve on imatinib?

TASIGNA has significantly more power to reduce progression vs. imatinib to AP/BC than imatinib in patients with newly diagnosed Ph+ CML.

What outcomes can I expect in imatinib-resistant or -intolerant patients?

Achieve high overall survival with TASIGNA in heavily pretreated imatinib-resistant or -intolerant patients.

Can tolerability help patients maintain therapy?

TASIGNA has a favorable tolerability profile in newly diagnosed patients.

TASIGNA Interactive Game

ENESTnd 24 Month Publication.

In newly diagnosed patients — More first-line power to reduce disease progression vs. imatinib.1

Dosing TASIGNA — Tips to help your patients incorporate TASIGNA into their routines.

References:
1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; June 2011.
2. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445-453.